The implementation of health technology assessment principles in public decisions concerning orphan drugs
Author:
Funder
OSSFOR - Osservatorio Farmaci Orfani -Roma
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00228-020-02855-7.pdf
Reference55 articles.
1. Richter T, Nestler-Parr S, Babela RM, Khan Z et al (2015) Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Health 18:906–9 1 4
2. EMA, Annual report on the use of the special contribution for orphan medicinal products (2017)
3. Schey C, Milanova T, Hutchings A (2011) Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis 6:62
4. Danzon PM (2018 Mar) Affordability challenges to value-based pricing: mass diseases, orphan diseases, and cures. Value Health 21(3):252–257
5. Paulden M, Stafinski T, Menon D, McCabe C (2015) Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. PharmacoEconomics 33:255–269
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions;Journal of Comparative Effectiveness Research;2024-02
2. How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries;Frontiers in Pharmacology;2022-07-19
3. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England;Value in Health;2021-12
4. A systematic review of moral reasons on orphan drug reimbursement;Orphanet Journal of Rare Diseases;2021-06-30
5. Beschleunigte Zulassung von Arzneimitteln: Herausforderungen für Patient:innen, Datenqualität und faire Preise;Arzneimittel-Kompass 2021;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3